Differentiating in a Crowded Cell & Gene Therapy Market

As the cell and gene therapy landscape grows more crowded, investors and developers are looking beyond breakthrough science to what truly sets programs apart. A recent MedCity News article features insights from Project Farma CEO, Anshul Mangal, who shares his perspective on how these trends align with what PF sees in the field.

Anshul highlights the importance of scalable platforms, regulatory viability, and commercialization readiness as critical differentiators. The article points to the FDA’s Platform Technology Designation and investors’ focus on early human data, along with the growing role of CDMO and academic partnerships, as clear signs that success now depends on both scientific innovation and the ability to delivery at scale. 

Click here to read the full article, The Discipline of Differentiation: Winning Strategies in a Crowded Cell and Gene Therapy Market.